Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population

Parkinson Disease Clinical Trial

— PARKA  

Official title:

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04322461
• Other study ID #: 2020-3436
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 1, 2022
• Est. completion date: December 15, 2024

Study information

• Verified date: May 2024
• Source: Université de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and after the intervention, along with endocannabinoids plasma concentrations.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 14
• Est. completion date: December 15, 2024
• Est. primary completion date: August 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Alzheimer's or parkinson disease diagnostic

• Stable medication associated with the disease

• Able to consent

• Presence of an accompanying person for the first and last visit.

• Ability to read and talk in French

Exclusion Criteria:

• MMSE < 20

• MCT or coconut oil supplementation

• Coconut allergy

• Cannabis, THC or CBD consumption

• Excessive alcohol consumption

• Physical activity 3x/week

• Presence of an metallic object in the body

• Impossibility to lay in dorsal decubitus for 40 minutes

• Cardiac disease

• Any uncontrolled disease that could interfer with the project.

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognition Disorders
• Cognitive Dysfunction
• Parkinson Disease

Intervention

Dietary Supplement:
• Betaquik MCT supplement
50g/day divided in 3. Breakfast, lunch and dinner

Locations

Country	Name	City	State
Canada	Centre de recherche sur le vieillissement	Sherbrooke	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
Université de Sherbrooke	Société des Produits Nestlé (SPN)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cognition	Measure of cognition with CANTAB	2 months, evaluation before and after intervention
Primary	Ketones	Measurement of ketones concentrations	2 months, evaluation before and after intervention
Secondary	Endocannabinoids	Endocannabinoids plasma concentration	2 months, evaluation before and after intervention